Products
Solutions
Resources
Pricing
Security
AI Agents
IP Search Agents
Novelty Search
FTO Search
Design FTO Search
IP Drafting Agents
SEP Agents
Engineering Agents
Find Solutions with TRIZ
Life Sciences Agents
SAR Data Extraction
Lead Compound
Materials Agents
Desktop
API & Integration
Pricing
Blog
Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.
3
results about "Chronic lymphocytic leukemia" patented technology
Filter
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A type of cancer that begins in the lymphocytes of bone marrow and extends into the blood.
An irak4 kinase inhibitor
Active
CN118978528B
Autoimmune condition
Autoimmune disease
The application discloses a novel IRAK4 inhibitor compound shown in formula (I) and use of the compound for preventing or treating IRAK4-mediated diseases, which include but are not limited to
rheumatoid arthritis
,
lupus erythematosus
and other autoimmune diseases, activated B-
cell
-like diffuse large B-
cell
lymphoma
,
chronic lymphocytic leukemia
, relapsed non-Hodgkin's
lymphoma
and other lymphomas.
View all
Owner:
SHANGHAI SINOV BIOPHARMACEUTICAL CO LTD
Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
Undetermined
ES3072972T3
Antiendomysial antibodies
Tyrosine-kinase inhibitor
This disclosure describes a pharmaceutical combination of an anti-CD19
antibody
and a Bruton's
tyrosine
kinase
(BTK) inhibitor for the treatment of non-
Hodgkin lymphoma
,
chronic lymphocytic leukemia
, and / or acute
lymphoblastic leukemia
.
View all
Owner:
INCYTE CORP
Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
Pending
US20260176355A1
Organic active ingredients
Pharmaceutical delivery mechanism
Antiendomysial antibodies
Pharmacy medicine
The present disclosure describes a pharmaceutical combination of an anti-CD19
antibody
and a BCL-2 inhibitor for the treatment of non-Hodgkin's
lymphoma
,
chronic lymphocytic leukemia
and / or acute
lymphoblastic leukemia
.
View all
Owner:
INCYTE CORP
Login to View More